Traws Pharma (TRAW) Revenue & Revenue Breakdown
Traws Pharma Revenue Highlights
Latest Revenue (Y)
$2.79B
Traws Pharma Revenue by Period
Traws Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $2.79B | 1234413.27% |
| 2024-12-31 | $226.00K | - |
| 2023-12-31 | $226.00K | - |
| 2022-12-31 | $226.00K | - |
| 2021-12-31 | $226.00K | -2.16% |
| 2020-12-31 | $231.00K | -89.42% |
| 2019-12-31 | $2.18M | 77.77% |
| 2018-12-31 | $1.23M | 56.04% |
| 2017-12-31 | $787.00K | -85.81% |
| 2016-12-31 | $5.55M | -51.59% |
| 2015-12-31 | $11.46M | 1332.00% |
| 2014-12-31 | $800.00K | -83.17% |
| 2013-12-31 | $4.75M | -89.71% |
| 2012-12-31 | $46.19M | 3006.25% |
| 2011-12-31 | $1.49M | - |
Traws Pharma generated $2.79B in revenue during NA 2025, up 1234413.27% compared to the previous quarter, and up 1207792.21% compared to the same period a year ago.
Traws Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | - | 100.00% |
| 2025-12-31 | - | 100.00% |
| 2025-09-30 | - | -100.00% |
| 2025-06-30 | $2.73M | 4694.74% |
| 2025-03-31 | $57.00K | - |
| 2024-12-31 | $57.00K | - |
| 2024-09-30 | $57.00K | 1.79% |
| 2024-06-30 | $56.00K | - |
| 2024-03-31 | $56.00K | -50.44% |
| 2023-12-31 | $113.00K | 98.25% |
| 2023-09-30 | $57.00K | -49.56% |
| 2023-06-30 | $113.00K | 101.79% |
| 2023-03-31 | $56.00K | -50.44% |
| 2022-12-31 | $113.00K | 98.25% |
| 2022-09-30 | $57.00K | -49.56% |
| 2022-06-30 | $113.00K | 101.79% |
| 2022-03-31 | $56.00K | -50.44% |
| 2021-12-31 | $113.00K | 98.25% |
| 2021-09-30 | $57.00K | -49.56% |
| 2021-06-30 | $113.00K | 101.79% |
| 2021-03-31 | $56.00K | -54.47% |
| 2020-12-31 | $123.00K | 86.36% |
| 2020-09-30 | $66.00K | -38.89% |
| 2020-06-30 | $108.00K | 107.69% |
| 2020-03-31 | $52.00K | -44.09% |
| 2019-12-31 | $93.00K | 47.62% |
| 2019-09-30 | $63.00K | -96.99% |
| 2019-06-30 | $2.09M | 2973.53% |
| 2019-03-31 | $68.00K | -62.01% |
| 2018-12-31 | $179.00K | 49.17% |
| 2018-09-30 | $120.00K | -88.56% |
| 2018-06-30 | $1.05M | 314.62% |
| 2017-12-31 | $253.00K | -52.62% |
| 2017-06-30 | $534.00K | -70.72% |
| 2016-12-31 | $1.82M | -50.99% |
| 2016-06-30 | $3.72M | -66.82% |
| 2015-12-31 | $11.22M | 4633.76% |
| 2015-06-30 | $237.00K | 3.95% |
| 2014-12-31 | $228.00K | -60.14% |
| 2014-06-30 | $572.00K | -81.22% |
| 2013-12-31 | $3.05M | 78.44% |
| 2013-06-30 | $1.71M | -96.27% |
| 2012-12-31 | $45.77M | 10850.24% |
| 2012-06-30 | $418.00K | - |
Traws Pharma generated - in revenue during Q2 2026, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Traws Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TRAW | Traws Pharma | $2.79B | - |
| BOLT | Bolt Biotherapeutics | $7.70M | $26.00K |
| EVGN | Evogene | $5.64M | $4.19M |
| IMRN | Immuron | $1.80M | $2.36M |
| BRTX | BioRestorative Therapies | $359.70K | $23.17K |
| DWTX | Dogwood Therapeutics | - | - |
| IMNN | Imunon | - | - |
| COCP | Cocrystal Pharma | - | $225.00K |
| CING | Cingulate | - | - |
| SNSE | Sensei Biotherapeutics | - | - |
| MBIO | Mustang Bio | - | - |